Major depressive disorder (MDD) is a prevalent and disabling psychiatric condition in Saudi Arabia, with genetic susceptibility remaining incompletely characterized. Reduced brain-derived neurotrophic factor (BDNF) activity has been implicated in MDD. The Val66Met polymorphism (rs6265), involving the substitution of valine (Val, G allele) with methionine (Met, A allele), impairs activity-dependent BDNF secretion. This study examined the frequency of Val66Met and its association with MDD in a Saudi cohort.
Materials and Methods:
A case-control study was conducted, including 87 patients with MDD (44 males, 43 females; mean age 44.2 ± 11.5 years) and 87 healthy controls (39 males, 48 females; mean age 28.7 ± 8.4 years). Genotyping was performed using tetra-primer amplification refractory mutation system–polymerase chain reaction. Unadjusted and age- and sex-adjusted logistic regression analyses were applied under genotype-specific, dominant, recessive, and allelic models.
Results:
The Val/Val (GG) genotype was more frequent in controls than patients (54.0% vs. 34.5%), whereas the Met/Met (AA) genotype was detected exclusively in patients (21.8% vs. 0%; χ2 = 22.80, p = 1.1 × 10−5). The Met (A) allele frequency was significantly higher in patients (43.7% vs. 23.0%; χ2 = 15.84, p = 6.9 × 10−5). Unadjusted analysis showed a protective effect of GG (OR = 0.45, 95% CI: 0.24–0.82) and a markedly increased risk associated with AA (OR = 49.81, 95% CI: 2.95–839.90). Dominant carriers (GA + AA) had increased odds of MDD (OR = 2.23), and each A allele conferred a higher risk (OR = 2.60). These associations remained significant after adjustment for age and sex.
Conclusion:
The BDNF Val66Met polymorphism is associated with MDD susceptibility in Saudis. The Met (A) allele, particularly in homozygosity, confers increased risk, while the Val/Val genotype appears protective, supporting population-specific genetic contributions to depression.
AlharbiAA, AljerianNA, BinhotanMS, et al.Digital surveillance of mental health care services in saudi arabia: Cross-sectional study of national e-referral system data. JMIR Public Health Surveill, 2025; 11:e64257–e64257; doi: 10.2196/64257
2.
Al‐SubaieAS, Al‐HabeebA, AltwaijriYA. Overview of the Saudi national mental health survey. Int J Methods Psych Res, 2020; 29(3):e1835; doi: 10.1002/mpr.1835
3.
ArosioB, GueriniFR, VoshaarRCO, et al.Blood Brain-Derived neurotrophic factor (BDNF) and major depression: Do we have a translational perspective? Front Behav Neurosci, 2021; 15:626906; doi: 10.3389/fnbeh.2021.626906
BitterI, SzekeresG, CaiQ, et al.Mortality in patients with major depressive disorder: A nationwide population-based cohort study with 11-Year Follow-Up. Eur Psychiatry, 2024; 67(1):e63; doi: 10.1192/j.eurpsy.2024.1771
7.
BothwellM. Functional interactions of neurotrophins and neurotrophin receptors. Annu Rev Neurosci, 1995; 18(1):223–253; doi: 10.1146/annurev.ne.18.030195.001255
8.
CastrénE, RantamäkiT. The role of BDNF and Its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol, 2010; 70(5):289–297; doi: 10.1002/dneu.20758
ChenZ-Y, PatelPD, SantG, et al.Variant Brain-Derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of Wild-Type BDNF in Neurosecretory cells and cortical neurons. J Neurosci, 2004; 24(18):4401–4411; doi: 10.1523/JNEUROSCI.0348-04.2004
11.
Colucci-D’AmatoL, SperanzaL, VolpicelliF. Neurotrophic factor BDNF, physiological functions and therapeutic potential in depression, neurodegeneration and brain cancer. Ijms, 2020; 21(20):7777; doi: 10.3390/ijms21207777
12.
CuiL, LiS, WangS, et al.Major depressive disorder: Hypothesis, mechanism, prevention and treatment. Signal Transduct Target Ther, 2024; 9(1):30; doi: 10.1038/s41392-024-01738-y
13.
DumanRS, MonteggiaLM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry, 2006; 59(12):1116–1127; doi: 10.1016/j.biopsych.2006.02.013
14.
EganMF, KojimaM, CallicottJH, et al.The BDNF Val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell, 2003; 112(2):257–269; doi: 10.1016/S0092-8674(03)00035-7
FerrerA, LabadJ, Salvat-PujolN, et al.BDNF genetic variants and methylation: Effects on cognition in major depressive disorder. Transl Psychiatry, 2019; 9(1):265; doi: 10.1038/s41398-019-0601-8
17.
HosangGM, ShilesC, TanseyKE, et al.Interaction between Stress and the BDNFVal66Met Polymorphism in Depression: A Systematic Review and Meta-Analysis. BMC Med, 2014; 12(1):7; doi: 10.1186/1741-7015-12-7
18.
HowardDM, AdamsMJ, ClarkeT-K, et al.; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci, 2019; 22(3):343–352; doi: 10.1038/s41593-018-0326-7
19.
HuangEJ, ReichardtLF. Neurotrophins: Roles in neuronal development and function. Annu Rev Neurosci, 2001; 24(1):677–736; doi: 10.1146/annurev.neuro.24.1.677
20.
KajumbaMM, Kakooza-MwesigeA, NakasujjaN, et al.Treatment-Resistant depression: Molecular mechanisms and management. Mol Biomed, 2024; 5(1):43; doi: 10.1186/s43556-024-00205-y
21.
LarsenAJ, TeobaldiG, Espinoza JeraldoRI, et al.Effectiveness of pharmacological and non-pharmacological interventions for treatment-resistant depression in older patients: A systematic review and meta-analysis. BMJ Ment Health, 2025; 28(1):e301324; doi: 10.1136/bmjment-2024-301324
22.
LicinioJ, DongC, WongM-L. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry, 2009; 66(5):488–497; doi: 10.1001/archgenpsychiatry.2009.38
23.
LohoffFW. Overview of the genetics of major depressive disorder. Curr Psychiatry Rep, 2010; 12(6):539–546; doi: 10.1007/s11920-010-0150-6
24.
LosenkovIS, MulderNJV, LevchukLA, et al.Association between BDNF gene variant Rs6265 and the severity of depression in antidepressant treatment-free depressed patients. Front Psychiatry, 2020; 11:38; doi: 10.3389/fpsyt.2020.00038
25.
MalomaneDK, WilliamsMP, HuberCD, et al.Patterns of Population Structure and Genetic Variation within the Saudi Arabian Population. bioRxiv, 2025:2025.01.10.632500; doi: 10.1101/2025.01.10.632500
26.
MengX, NavolyG, GiannakopoulouO, et al.; BioBank Japan Project. Multi-Ancestry genome-wide association study of major depression aids locus discovery, fine mapping, gene prioritization and causal inference. Nat Genet, 2024; 56(2):222–233; doi: 10.1038/s41588-023-01596-4
27.
ParkH, PooM. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci, 2013; 14(1):7–23; doi: 10.1038/nrn3379
28.
Pérez-GutiérrezAM, RoviraP, GutiérrezB, et al.Influence of BDNF Val66Met genetic polymorphism in major depressive disorder and body mass index: Evidence from a meta-analysis of 6481 individuals. J Affect Disord, 2024; 344:458–465; doi: 10.1016/j.jad.2023.10.024
29.
RibeiroL, BusnelloJV, CantorRM, et al.The brain-derived neurotrophic factor Rs6265 (Val66Met) polymorphism and depression in mexican-americans. Neuroreport, 2007; 18(12):1291–1293; doi: 10.1097/WNR.0b013e328273bcb0
30.
SchumacherJ, JamraRA, BeckerT, et al.Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry, 2005; 58(4):307–314; doi: 10.1016/j.biopsych.2005.04.006
31.
SheikhHI, HaydenEP, KryskiKR, et al.Genotyping the BDNF Rs6265 (Val66met) Polymorphism by one-step amplified refractory mutation System PCR. Psychiatr Genet, 2010; 20(3):109–112; doi: 10.1097/YPG.0b013e32833a2038
32.
ShkundinA, HalarisA. Associations of BDNF/BDNF-AS SNPs with depression, schizophrenia, and bipolar disorder. J Pers Med, 2023; 13(9):1395; doi: 10.3390/jpm13091395
33.
AutonA, BrooksLD, DurbinRM, et al.; The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature, 2015; 526(7571):68–74; doi: 10.1038/nature15393
34.
VerhagenM, Van Der MeijA, Van DeurzenPAM, et al.Meta-Analysis of the BDNF Val66Met polymorphism in major depressive disorder: Effects of gender and ethnicity. Mol Psychiatry, 2010; 15(3):260–271; doi: 10.1038/mp.2008.109
35.
WangY, LiO, LiN, et al.Association between the BDNF Val66Met Polymorphism and Major Depressive Disorder: A Systematic Review and Meta-Analysis. Front Psychiatry, 2023; 14:1143833; doi: 10.3389/fpsyt.2023.1143833
36.
ZhangH, OzbayF, LappalainenJ, et al.Brain derived neurotrophic factor (BDNF) gene variants and alzheimer’s disease, affective disorders, posttraumatic stress disorder, schizophrenia, and substance dependence. Am J Med Genet B Neuropsychiatr Genet, 2006; 141B(4):387–393; doi: 10.1002/ajmg.b.30332
37.
ZhaoM, ChenL, YangJ, et al.BDNF Val66Met polymorphism, life stress and depression: A meta-analysis of gene-environment interaction. J Affect Disord, 2018; 227:226–235; doi: 10.1016/j.jad.2017.10.024
38.
ZouY-F, YeD-Q, FengX-L, et al.Meta-Analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol, 2010; 20(8):535–544; doi: 10.1016/j.euroneuro.2009.12.005
